Bladder cancer is a common cancer of the urinary tract. It is the fourth leading cause of cancer-related death among men and the seventh among women. Clinical management of bladder cancer is challenging because of the heterogeneity among bladder tumors with respect to invasion and metastasis, frequent occurrence of new tumors in the bladder among patients treated with bladder preservation treatments and poor prognosis of patients with tumors that invade the bladder muscle and beyond. Due to these factors it has been said that the cost per patient of bladder cancer, from diagnosis to death is the highest of all cancers. In addition to it being a significant health problem, bladder cancer is an interesting cancer to study in many ways than one. For example, Environmental factors such as cigarette smoking and other carcinogens play a major role in the development of transitional carcinoma of the bladder, whereas, schitosomasis, a protozoan infection results in squamous cell carcinoma of the bladder. Different molecular pathways with distinct molecular signatures appear to be involved in the development of low-grade versus high-grade bladder tumors. Currently being monitored by an invasive endoscopic procedure, cystectomy, with urine cytology as an adjunct, bladder cancer is at the forefront of developing cancer biomarkers for non-invasive detection. Due to the differences in the invasive and metastatic potential of bladder tumors, treatment options differ depending upon tumor grade and stage. New advances are being made in treatment options to improve the outcome and quality of life for patients with bladder cancer. Similarly, new molecular nomograms are being discovered to predict treatment outcome so that individualized treatment options can be offered to patients.
DNA Tumor Viruses will focus on the DNA viruses in the human population that are associated with cancers. It will cover most of the viruses that are thought to contribute to human malignancy. This book will represent a comprehensive review of the field of DNA tumor virology. Right now, while there are books out there that cover individual viruses that will be also covered in this book, there is no single book that covers this topic comprehensively. The main textbook in this market, Fields, which is referred to by both reviewers, covers some of these topics but on a lower level. The only two books that are nearly as comprehensive as this one are Human Tumor Viruses, which was published by the American Society for Microbiology in 1998 and is quite outdated, and Viruses, Cell Transformation, and Cancer, which was published by Elsevier in 2001. Our book will be the only current, comprehensive review of its kind in the market.
Hector is being hectored by an unlikely bully: a talking brain tumor. And it´s not just a talking brain tumor. It´s a know-it-all, pain-in-the-arse, jibber-jabbering brain tumor that names itself Jack, and insists on coaching Hector through life even as it´s threatening to take his life away. It´s a pretty good coach, actually. With Jack in control of Hector´s speech and brain chemicals, Hector suddenly finds himself with a cool haircut, a new fashion sense, and tactics for snogging previously unattainable hottie Uma Upshaw. But when Jack begins to force increasingly questionable decisions and behavior, Hector has to find a way to turn the tables before it´s too late for both of them. Delightfully twisted, desperately funny, and deeply moving, this novel is also the winner of the Booktrust Teenage Prize in the United Kingdom.
The request from Professor Jörg Klekamp for me to write the foreword for this monograph was an appealing challenge. Prior to the era of microneu- surgery, I was firmly involved in the surgery of spinal lesions, and achieved surgical removal of spinal arteriovenous malformations (AVMs) on 12 - tients in the years between 1960 and 1965. Microneurosurgical techniques were introduced in Zurich in 1962, and since then I have applied these techniques to the exploration of the various spinal lesions: 182 herniated discs, 78 spinal cord AVMs, and 263 spinal tumors (46 epidural, 94 ext- medullary, and 123 intramedullary tumors). These have been published in a preliminary paper only, for I was unable to accomplish completion of the planned Volume V in my Microneurosurgery series within an adequate time frame. I therefore admire the achievement of Klekamp and Samii, who present to us a most comprehensive work. This monograph is outstanding in many aspects, providing an overview of the clinical experiences gained in a single neurological institution over a period of 25 years between 1978 and 2003, consisting of 1081 spinal tumors treated in 868 patients, with 973 operations (intramedullary tumors in 198 patients, extramedullary tumors in 446 patients, and epidural tumors in 329 patients). The entire cohort of patients was explored surgically by app- ing microsurgical techniques.
The fact that tumors are composed of both tumor cells and host cells has long been known. These tumor-associated cells include vascular endothelial cells and pe- cytes, as well as inflammatory cells such as neutrophils, monocytes, macrophages, mast cells and eosinophils, and lymphocytes. The tumor cells also interact with stromal cells and with elements of the tissue extracellular matrix. What has been less appreciated is the role that these cells could have in modulating the growth, invasion, and metastasis of the tumor. Early on, the elements of what we now call the tumor microenvironment were considered to be more or less innocent bysta- ers to the role of the tumor cells as they grew and invaded local sites. Today, there is an increased understanding of the critical role of the tumor microenvironment as dramatically influencing the course of tumor development and dissemination. This volume represents a superb compilation of the latest thoughts and data regarding the role of each essential component of the tumor microenvironment in cancer development and progression. Perhaps, the earliest recognition of the role of nonmalignant cells as cancer re- lators was the recognition that lymphocytes can participate in what was termed immune surveillance in the 1960s. Our understanding of tumor immunity has improved markedly since then, and there are now successful clinical studies sh- ing the potential use of immune-based therapies in cancer treatment.
th At the 6 International Cancer Congress held meantime the new committee has endeavored at Sao Paulo a list of tumors, intended to produce a simple, generally acceptable primarily for the purpose of statistical codi tumor nomenclature founded on logical prin fication, was presented and accepted with ciples of pathology. A first draft without pictures was published in slight alterations only. This list had been prepared by the Committee on Tumor Nomen ´´ACTA´´ Vol. XIV No. 3-1958, which is now clature and Statistics, of the International followed by an illustrated edition. We are Union against Cancer, under the chairman greatly indebted to all the authors and publish ship of Dr. PERRY. It had also served as ers for permission to use their illustrations and a basis for the somewhat simplified code for providing us with the original prints. submitted to WHO, which circulated it Unfortunately it was not possible to obtain as document WHOjHSjCANCj24.1. An al the original prints for the figures from the Atlas of Tumor Pathology; we therefore had phabetical index to the code, mostly ba sed on terms in use in the United States, to use the printed illustrations for repro constitutes part 2 of this document (WHOj duction and are grateful to the Armed Forces Institute of Pathology for permission HSjCAN/C24.2). The preparation of a list of descriptive terms to use them.
Creating clinical guidelines is a modern trend. Published studies pertaining to a given theme are collected, their credibility evaluated, and then treatment options in the form of evidence-based guidelines are offered. There are a number of guidelines for the treatment of thyroid tumors that have established positions in clinical practice in North America and in Western European countries. In Japan, however, where radioisotope facilities are of limited availability, treatment plans for differentiated thyroid cancer differ considerably from those of America and Europe, and the associated clinical guidelines need modification before they can be adopted. In addition, although thyroid tumor is a common disease in endocrine practice, its management can differ even among specialists. Thus, a Japanese clinical guideline for the treatment of thyroid tumor was desired by many clinicians. As a combination of evidence-based and consensus-based guidelines for the treatment of thyroid tumor, this book offers alternatives to conventional approaches in the West. Ultimately, the authors hope the guideline will lead to the best possible treatment for patients all over the world in the not-distant future.
Tumor Neurosurgery provides information on the basic knowledge and clinical management required for optimal care of neurooncology patients. Providing an up-to-date synopsis of the field of tumor neurosurgery, the book covers the most common sites and tumor pathologies encountered by neurosurgeons. The chapters are organized under broad topics, including investigative studies, perioperative care and the role of newer techniques. The clinical management of CNS tumors in adults and children is described, including spinal tumors, both intradural and extradural. This book provides coverage of relevant topics in the field of tumor neurosurgery, for residents and registrars in training, and for recent graduates of training programs.
Knowledge about the etiology and diagnosis as well as treatment concepts of neu- oncologic diseases is rapidly growing. This turnover of knowledge makes it dif? cult for the physician engaged in the treatment to keep up to date with current therapies. This book sets out to close the gap and pursues several innovative concepts. As a comprehensive text on neuro-oncology, its chapters are interconnected, but at the same time some chapters or subdivisions are so thoroughly assembled that the whole volume gives the impression of several books combined into one. Neuropathology is treated in an extensive and clearly structured section. The int- ested reader ? nds for each tumor entity the latest well-referenced consensus rega- ing histologic and molecular pathology. Through this book-in-the-book concept, information on neuropathology is readily at hand in a concise form and without ov- loading the single chapters. Pediatric neuro-oncology differs in many entities from tumors in adult patients; also, certain tumors of the CNS are typically or mainly found only in the child. Therefore, pediatric neuro-oncology was granted its own, book-like section. Tumor entities that are treated differently in children and adults are included both in the pediatric neuro-oncology section and in the general section. Entities that typically occur only in the child and adolescent are found in the pediatric section in order to avoid redundancies.